Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Standardized Assays Developed to Quantify Human Proteins

By BiotechDaily International staff writers
Posted on 30 Dec 2013
Image: Orbitrap Velos Pro hybrid ion trap mass spectrometer (Photo courtesy of Thermo Scientific).
Image: Orbitrap Velos Pro hybrid ion trap mass spectrometer (Photo courtesy of Thermo Scientific).
The feasibility of large-scale standardized protein measurements, which are necessary for validation of disease biomarkers, has been developed.

Multiple reaction monitoring (MRM) mass spectrometry has been successfully applied to monitor targeted proteins in biological specimens, raising the possibility that assays could be configured to measure all human proteins.

Scientists at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) in collaboration with other intuitions targeted a protein-detection approach that has the potential to systematically and reliably measure the entire human repertoire of proteins, known as the proteome. The MRM technique can simultaneously and precisely detect the abundance of hundreds of proteins in many different samples. The teams of investigators were able to reproduce measurements of 319 proteins from human breast cancer cells, showing that the method can be standardized across laboratory and international boundaries.

This method enabled highly specific, precise, multiplex, quantification of a minimum of 170 proteins in 20 clinical samples per instrument per day— no other existing technology has this power. Because the mass spectrometry technique is targeted, meaning the scientists can tune the instruments to look for a specific subset of proteins in cancer cells or other sample types, it can detect the presence of proteins of interest at much lower levels in minute blood samples or biopsies than a nontargeted tactic.

Amanda Paulovich, MD, the senior author of the study, said, “This method has the potential to completely revolutionize how we measure human proteins. Having a global resource for standardized quantification of all human proteins would set new standards that would undoubtedly increase the reproducibility of preclinical research, which would have a dramatic impact on the translation of novel therapeutics and diagnostics. Right now, you can't make robust measurements of most human proteins. More than 10 years after the human genome has been sequenced and we have the full catalog of molecules as important as proteins, we still can't study the human proteome with any kind of throughput in a standardized, quantitative manner.” The study was published on December 8, 2013, in the journal Nature Methods.

Related Links:

Fred Hutchinson Cancer Research Center



Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.